Nauticus Robotics stock rises after regaining Nasdaq compliance

Investing.com -- Hedge fund giant Citadel plans to return approximately $5 billion in profits from 2025 to investors at the start of next year, according to a CNBC report on Tuesday.

The firm’s flagship Wellington multi-strategy fund achieved a 9.3% gain through last week.

Unlock premium analysis and insights with InvestingPro - get 55% off today

The planned distribution represents only a portion of Citadel’s 2025 profits. The decision to return capital stems from what fund managers perceive as limited investment opportunities heading into 2026. Following this distribution, Citadel will begin 2026 managing $67 billion in assets, down from its current $72 billion.

Profit distributions are not an annual practice for Citadel, but the firm has returned substantial capital to investors over recent years. Including the anticipated 2025 distribution, Citadel will have returned $32 billion in profits to investors since 2017.

Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for the company in blood disorder treatments.

The death occurred on December 14 after the patient experienced serious adverse events, including a cerebellar infarction (stroke) followed by cerebral hemorrhage (brain bleeding), according to a statement from the European Haemophilia Consortium.

The individual, who had hemophilia A with inhibitors, was participating in a long-term open-label extension study of marstacimab (marketed as Hympavzi). The patient had previously participated in the active treatment phase of the parent trial in 2022 and moved into the extension study in 2023.

The fatal event occurred while the patient was receiving marstacimab prophylaxis followed by recombinant factor VIIa, which was administered for perioperative hemostatic management after minor surgery.

Pfizer is working with the study investigator and an independent external Data Monitoring Committee to conduct a comprehensive review of the circumstances surrounding the event. This includes evaluating underlying medical conditions, concurrent medications, and the potential relationship to the study treatment.

The company has notified relevant regulatory authorities and investigators, and surgical management protocols within the marstacimab development program are under review.

Thrombotic events are considered an adverse event for rebalancing therapies such as marstacimab, which works by inhibiting tissue factor pathway inhibitor to enhance thrombin generation. Similar events have been reported with other non-factor hemophilia treatments, particularly in perioperative contexts and when used in combination with clotting factor concentrates or bypassing agents.

Hympavzi was approved last year by regulators in the US and Europe to prevent or reduce the frequency of bleeding episodes in certain patients with hemophilia. The drug was billed as the first of its kind, targeting a protein in the blood clotting process rather than replacing clotting factor.

While the drug has received regulatory approval from the European Medicines Agency for the treatment of hemophilia A or B in patients without inhibitors, its use in patients with inhibitors has not been approved and continues to be evaluated in clinical studies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Morocco stocks were higher after the close on Tuesday, as gains in the Banking, Beverage and Transport sectors led shares higher.

At the close in Casablanca, the Moroccan All Shares gained 0.01% to hit a new 1-month high.

The best performers of the session on the Moroccan All Shares were Wafa Assurance (CSE:WAA), which rose 3.42% or 167.00 points to trade at 5,049.00 at the close. Meanwhile, SMI (CSE:SMI) added 3.31% or 121.00 points to end at 3,779.00 and Lesieur Cristal (CSE:LES) was up 2.74% or 8.00 points to 300.00 in late trade.

The worst performers of the session were Involys (CSE:INV), which fell 5.83% or 13.00 points to trade at 210.00 at the close. M2M Group (CSE:M2M) declined 4.10% or 19.50 points to end at 456.00 and Sanlam Maroc SA (CSE:SAH) was down 3.86% or 79.00 points to 1,970.00.

Falling stocks outnumbered advancing ones on the Casablanca Stock Exchange by 37 to 22 and 5 ended unchanged.

Shares in SMI (CSE:SMI) rose to 5-year highs; rising 3.31% or 121.00 to 3,779.00.

Crude oil for February delivery was down 0.33% or 0.19 to $57.82 a barrel. Elsewhere in commodities trading, Brent oil for delivery in February fell 0.42% or 0.26 to hit $61.81 a barrel, while the February Gold Futures contract rose 0.06% or 2.50 to trade at $4,471.90 a troy ounce.

EUR/MAD was up 0.16% to 10.76, while USD/MAD fell 0.16% to 9.13.

The US Dollar Index Futures was down 0.23% at 97.72.

Investing.com -- Highway Holdings Limited (NASDAQ:HIHO) stock surged 87.8% Tuesday after the company announced it signed a letter of intent to acquire a 51% stake in German-based Regent-Feinbau Adermann GmbH.

The proposed acquisition, targeted to close by the end of March 2026, would be primarily for cash with a smaller portion in unregistered shares. The transaction remains subject to due diligence, definitive agreement negotiation, and customary closing conditions.

Founded in 1949, Regent-Feinbau specializes in precision sheet metal components and welded assemblies, serving automotive, commercial vehicle, aerospace, and industrial sectors. The company is a certified manufacturing specialist with capabilities in laser cutting, bending, forming technology, component assembly, and advanced welding.

Highway Holdings’ Chairman, President and CEO Roland Kohl described the potential acquisition as part of the company’s strategy to "reinvigorate" its OEM business, which has experienced customer losses due to global business challenges during and after COVID.

The acquisition would enhance Highway Holdings’ capabilities in thick sheet metal cutting, bending, and welding - allowing it to target the Chinese automotive market, which Kohl noted has a positive growth rate estimated at about $660 billion with projected growth exceeding 2% over the next five years.

Despite 35 years of operations in China, Highway Holdings has never directly targeted the local Chinese market beyond supporting international OEM customers with local presence.

The company reported it has a strong financial foundation for this and potentially other acquisitions, with approximately $5.3 million in cash and cash equivalents (about $1.20 per share) and substantially no debt.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Nestle has finalized the sale of its remaining 40% stake in packaged meat business Herta Foods to Spanish company Casa Tarradellas, the company announced Tuesday.

The financial terms of the transaction were not disclosed.

The sale marks the end of the joint venture that was established in 2019 when Nestle initially sold a stake in Herta to Casa Tarradellas.

Nestle had previously placed Herta charcuterie, which specializes in cold cuts and meat-based products, under strategic review as the unit no longer aligned with the company’s strategic focus on healthy nutrition and plant-based offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Meta Platforms presents both risks and opportunities heading into 2026, according to Baird, which frames the stock as a “battleground” following recent underperformance. 

Unlock more analyst ratings and AI insights with InvestingPro - get 55% off today

Analyst Colin Sebastian urged investors to “be opportunistic buyers,” noting that while near-term sentiment risks remain, “embedded expectations are in better balance vs. three months ago.”

Baird highlighted several potential catalysts for a more constructive outlook, including a “clearing event with Q1 guidance/margin outlook,” the “launch of next Llama model built by TBD Lab,” updates to Meta AI, and “ramping WhatsApp and Threads monetization.” 

The analyst also pointed to ongoing improvements in ranking, relevance, and engagement metrics, as well as further penetration of Adv+ automation and the option value from wearables and custom silicon.

The bear case, Baird noted, stems largely from concerns that Meta is “lagging in AI,” with limited visibility into how the narrative will evolve. 

Additional headwinds are said to include “uncertain ROI on infrastructure investments, tougher revenue and KPI comps, slower monetization of newer surfaces,” and TikTok’s resurgence in the U.S.

Despite these challenges, Sebastian argued that many concerns are now “appropriately embedded in expectations,” after META underperformed the Nasdaq by more than 20 percentage points over the past six months. 

Baird also cited the company’s track record navigating disruptions such as the mobile app transition and IDFA headwinds.

“Shares trade at roughly 10-11x NTM EV/EBITDA, slightly below historical averages and peers, including Alphabet, Reddit, and Snap,” stated Sebastian. 

The analyst concluded that as Meta demonstrates progress with AI and Llama, investors may increasingly focus on “market-expanding opportunities” in 2026.